February / March #99 : Norvir up by 400% - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Daring to Declare

Old Drugs, New Tricks

Jailbait

Matchmakers

www.safesexcity.com

Go, Girl!

Earthwatch

Tribute: Greg Smith

Service With a Smile

Karma Chameleon

That ’80s Show

Criminal Neglect

NEG & POS

ComicRelief

In Memoriam

The Great Depression

Briefs

Getting Down

Norvir up by 400%

Guidelines Re-revised

Genital Hospital

Immune Up

Do Single HIVers Die Faster?

More than 50 percent

Growing Up Positive

Gum Up

Quick Study: Vitamins & Minerals

Editor's Letter

Mailbox

Unhappy Meal



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

February / March 2004

Norvir up by 400%

by Laura Whitehorn

Boosting price, not potency

The protease inhibitor Norvir (ritonavir), approved in 1996, is most often used today to help other HIV meds give your virus the one-two punch. Now its maker, Abbott Laboratories, is boosting the booster’s price—by about 400 percent, according to John Leonard, MD, who has long headed Abbott’s Norvir research and development. Leonard says the hike will help pay to improve the PI, though this won’t lessen the pill’s common gastrointestinal side effects: Leonard says reformulation is meant to make Norvir more stable so it won’t need refrigeration.

The boosted booster will cost $8.57 per 100-mg dose (old price: $1.71); Abbott’s PI Kaletra (ritonavir plus lopinavir) won’t go up. (Do they want you to switch from a Norvir-boosted competitor’s PI to Kaletra?) Leonard adds that the original dose was 1,200 mg—about $20 a day—and that 80 percent of Norvir takers now take 100 mg, with only 1 percent on the heftier dose.

That’s market share trumping medical care, and Abbott has a history of being sued over pricing practices. The hike shouldn’t have much immediate impact on HIVers, according to Project Inform’s Martin Delaney, who points out that the price Abbott charges ADAP is frozen at least until early 2005. And Abbott says it’s expanding Norvir’s Patient Assistance Program, “basically removing income limits,” according to PR rep Nicole Wesley, so that all Norvir takers without private insurance or public assistance can get it free (call 800.222.6885).

But, Delaney adds, the longer-term results of this pill-ticket jack-up look less benign—forcing doctors to avoid prescribing regimens including Norvir and setting exorbitant standards for HIV med pricing. The AIDS Treatment Activist Coalition (ATAC) has sent a letter urging Abbott to “reconsider this shameful and destructive path.”




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.